FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383877432> ?p ?o ?g. }

• W4383877432 endingPage "1919" @default.
• W4383877432 startingPage "1919" @default.
• W4383877432 abstract "Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited treatment options exist. However, its poor physicochemical properties limit its application. This study aimed to formulate and evaluate an ACV-loaded red clay nanodrug delivery system exhibiting an effective cytotoxicity. The study focused on the preparation of a complex between ACV and red clay (RC) using sucrose stearate (SS) (nanocomplex F1) as an immediate-release drug-delivery system for melanoma treatment. The synthesized nanocomplex, which had nanosized dimensions, a negative zeta potential and the drug release of approximately 85% after 3 h, was found to be promising. Characterization techniques, including FT-IR, XRD and DSC-TGA, confirmed the effective encapsulation of ACV within the nanocomplex and its stability due to intercalation. Cytotoxicity experiments conducted on melanoma cancer cell lines SK-MEL-3 revealed that the ACV release from the nanocomplex formulation F1 effectively inhibited the growth of melanoma cancer cells, with an IC50 of 25 ± 0.09 µg/mL. Additionally, ACV demonstrated a significant cytotoxicity at approximately 20 µg/mL in the melanoma cancer cell line, indicating its potential repurposing for skin cancer treatment. Based on these findings, it can be suggested that the RC-SS complex could be an effective drug delivery carrier for localized cancer therapy. Furthermore, the results of an in silico study suggested the addition of chitosan to the formulation for a more effective drug delivery. Energy and interaction analyses using various modules in a material studio demonstrated the high stability of the composite comprising red clay, sucrose stearate, chitosan and ACV. Thus, it could be concluded that the utilization of the red clay-based drug delivery system is a promising strategy to improve the effectiveness of targeted cancer therapy." @default.
• W4383877432 created "2023-07-12" @default.
• W4383877432 creator A5022127806 @default.
• W4383877432 creator A5023095637 @default.
• W4383877432 creator A5027440113 @default.
• W4383877432 creator A5035978995 @default.
• W4383877432 creator A5037413888 @default.
• W4383877432 creator A5047664930 @default.
• W4383877432 creator A5079291750 @default.
• W4383877432 creator A5080027922 @default.
• W4383877432 creator A5084424869 @default.
• W4383877432 creator A5092443964 @default.
• W4383877432 date "2023-07-10" @default.
• W4383877432 modified "2023-09-26" @default.
• W4383877432 title "Development of a Novel Red Clay-Based Drug Delivery Carrier to Improve the Therapeutic Efficacy of Acyclovir in the Treatment of Skin Cancer" @default.
• W4383877432 cites W12127012 @default.
• W4383877432 cites W1983665580 @default.
• W4383877432 cites W1985607453 @default.
• W4383877432 cites W1989229997 @default.
• W4383877432 cites W1993850123 @default.
• W4383877432 cites W2010441623 @default.
• W4383877432 cites W2090243647 @default.
• W4383877432 cites W2114918609 @default.
• W4383877432 cites W2600732159 @default.
• W4383877432 cites W2604973084 @default.
• W4383877432 cites W2748981560 @default.
• W4383877432 cites W2884224512 @default.
• W4383877432 cites W3021477764 @default.
• W4383877432 cites W3111663739 @default.
• W4383877432 cites W3126635410 @default.
• W4383877432 cites W3131769770 @default.
• W4383877432 cites W3151943314 @default.
• W4383877432 cites W3175813596 @default.
• W4383877432 cites W3199280655 @default.
• W4383877432 cites W3204904362 @default.
• W4383877432 cites W3206202754 @default.
• W4383877432 cites W4210366548 @default.
• W4383877432 cites W4280570366 @default.
• W4383877432 cites W4280632742 @default.
• W4383877432 cites W4282937816 @default.
• W4383877432 cites W4309939011 @default.
• W4383877432 doi "https://doi.org/10.3390/pharmaceutics15071919" @default.
• W4383877432 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37514105" @default.
• W4383877432 hasPublicationYear "2023" @default.
• W4383877432 type Work @default.
• W4383877432 citedByCount "0" @default.
• W4383877432 crossrefType "journal-article" @default.
• W4383877432 hasAuthorship W4383877432A5022127806 @default.
• W4383877432 hasAuthorship W4383877432A5023095637 @default.
• W4383877432 hasAuthorship W4383877432A5027440113 @default.
• W4383877432 hasAuthorship W4383877432A5035978995 @default.
• W4383877432 hasAuthorship W4383877432A5037413888 @default.
• W4383877432 hasAuthorship W4383877432A5047664930 @default.
• W4383877432 hasAuthorship W4383877432A5079291750 @default.
• W4383877432 hasAuthorship W4383877432A5080027922 @default.
• W4383877432 hasAuthorship W4383877432A5084424869 @default.
• W4383877432 hasAuthorship W4383877432A5092443964 @default.
• W4383877432 hasBestOaLocation W43838774321 @default.
• W4383877432 hasConcept C109316439 @default.
• W4383877432 hasConcept C121608353 @default.
• W4383877432 hasConcept C126322002 @default.
• W4383877432 hasConcept C155672457 @default.
• W4383877432 hasConcept C171250308 @default.
• W4383877432 hasConcept C178790620 @default.
• W4383877432 hasConcept C185592680 @default.
• W4383877432 hasConcept C192562407 @default.
• W4383877432 hasConcept C202751555 @default.
• W4383877432 hasConcept C21951064 @default.
• W4383877432 hasConcept C2777658100 @default.
• W4383877432 hasConcept C2777789703 @default.
• W4383877432 hasConcept C2779820397 @default.
• W4383877432 hasConcept C2780035454 @default.
• W4383877432 hasConcept C502942594 @default.
• W4383877432 hasConcept C55493867 @default.
• W4383877432 hasConcept C71924100 @default.
• W4383877432 hasConcept C86181022 @default.
• W4383877432 hasConcept C96232424 @default.
• W4383877432 hasConcept C98274493 @default.
• W4383877432 hasConceptScore W4383877432C109316439 @default.
• W4383877432 hasConceptScore W4383877432C121608353 @default.
• W4383877432 hasConceptScore W4383877432C126322002 @default.
• W4383877432 hasConceptScore W4383877432C155672457 @default.
• W4383877432 hasConceptScore W4383877432C171250308 @default.
• W4383877432 hasConceptScore W4383877432C178790620 @default.
• W4383877432 hasConceptScore W4383877432C185592680 @default.
• W4383877432 hasConceptScore W4383877432C192562407 @default.
• W4383877432 hasConceptScore W4383877432C202751555 @default.
• W4383877432 hasConceptScore W4383877432C21951064 @default.
• W4383877432 hasConceptScore W4383877432C2777658100 @default.
• W4383877432 hasConceptScore W4383877432C2777789703 @default.
• W4383877432 hasConceptScore W4383877432C2779820397 @default.
• W4383877432 hasConceptScore W4383877432C2780035454 @default.
• W4383877432 hasConceptScore W4383877432C502942594 @default.
• W4383877432 hasConceptScore W4383877432C55493867 @default.
• W4383877432 hasConceptScore W4383877432C71924100 @default.
• W4383877432 hasConceptScore W4383877432C86181022 @default.
• W4383877432 hasConceptScore W4383877432C96232424 @default.
• W4383877432 hasConceptScore W4383877432C98274493 @default.

• next